Results

Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 22.457 (Stand 01. November 2023)
Amgevita® (Adalimumab)202
Benepali® (Etanercept)1141
Cimzia® (Certolizumab)1019
Enbrel® (Etanercept)2872
Erelzi® (Etanercept)491
Flixabi® (Infliximab)10
Hulio® (Adalimumab)221
Humira® (Adalimumab)2908
Hyrimoz® (Adalimumab)193
Idacio® (Adalimumab)59
Imraldi® (Adalimumab)192
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)118
Kevzara® (Sarilumab)207
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)57
Olumiant® (Baricitinib)527
Orencia® (Abatacept)967
Remicade® (Infliximab)762
Remsima® (Infliximab)19
Rinvoq® (Upadacitinib)289
Rixathon® (Rituximab)20
RoActemra® (Tocilizumab)1371
Ruxience® (Rituximab)1
Simponi® (Golimumab)466
Xeljanz® (Tofacitinib)394
Yuflyma® (Adalimumab)15
Zessly® (Infliximab)2
Kontrollen6370